- Home
- ALXO vs IIF Comparison
ALXO vs IIF Comparison
Compare ALXO & IIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALXO | IIF |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.8M | 206.3M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALXO | IIF |
|---|---|---|
| Price | $1.67 | $21.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 941.0K | 36.6K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.94% |
| EPS Growth | ★ 26.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $19.83 |
| 52 Week High | $2.66 | $28.37 |
Technical Indicators
Market Signals| Indicator | ALXO | IIF |
|---|---|---|
| Relative Strength Index (RSI) | 35.80 | 38.81 |
| Support Level | $1.54 | $21.11 |
| Resistance Level | $2.24 | $22.46 |
| Average True Range (ATR) | 0.11 | 0.37 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 2.38 | 24.65 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About IIF Morgan Stanley India Investment Fund Inc.
Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.